• 11 July 2011
  • News
  • By

Sets sight on mass spectrometer products

Revenue 186 crore*
Shimadzu Analytical (India)
MD: Mr Senya Imamichi
Business: Analytical and Scientific Instrumentation
Start-up Year: 2006
Address: 1A/B Rushabh Chambers, Makwana Road, Marol,
Andheri (East), Mumbai – 400059
Tel: +91-22-29204741
Fax: +91-22-29201678
Website: www.shimadzu.com
Life sciences, with 70 percent revenue share, continues to be a major contributor to Shimadzu  Analytical's (India) overall revenue

Shimadzu Analytical (India), a subsidiary of Shimadzu Corporation, focuses on offering technologies in the field of analytical and scientific instrumentation, process control instrumentation, and environmental monitoring.

For fiscal 2010-11, the company clocked revenue of 186 crore as against 141 crore in 2009-10. The growth has primarily been due to the recovery of the India life sciences market after May 2010.

The Indian subsidiary completed five years of direct operations in India in April 2011. Started in 2006, in India, Shimadzu presently has five marketing partners namely Spinco Biotech, Toshvin Analytical, Swan Environmental, Saksham Analytical Instruments and Amkette Analytics. Shimadzu has been operating in the India life sciences space for the past 40 years through these distributors.

Life sciences, with 70 percent revenue share, continues to be a major contributor to the subsidiary's overall revenue. Over the past one year, the pharma companies, have been making considerable investments in high-end research activities. This is due to the gradual shift of India from a drug development to a drug discovery destination.

This in turn has had a positive affect on Shimadzu India's overall life sciences revenue. “Indian companies are now looking at NCE research, which requires high-end technology. Moreover, many pharma companies are particular about quality control. This has proved to be an advantage for Shimadzu India,” says Mr Senya Imamichi, managing director, Shimadzu Analytical (India).

In the coming years, Shimadzu India will focus on its mass spectrometer product, as pharma companies are stepping-up focus on high-end NCE research.
The company has also invested in expansion of its infrastructure, customer service and training activities. Says Mr Imamichi, “Since 2006, we have doubled our infrastructure space and also doubled investments in customer services.”

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email